Eyenuk, a global artificial intelligence medical technology company that specializes in eye screening, announced on 4/11/2019 its EyeScreen™ Human + AI Diagnostic Service for diabetic retinopathy (DR). It combines the high accuracy of AI-based diagnostics with the accepted practice of human grading in order to improve accuracy, reduce wait times, and increase access. With this new technology, any physician can identify silently progressing diabetic retinopathy sooner and begin intervention faster, thus improving patient outcomes and reducing the incidence of vision loss due to DR.  The eye-screening industry is attracting various players. For example, Topcon, a major Japanese optical equipment firm, is also developing AI for eye-screening.